MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3560
+0.0140
+4.09%
After Hours: 0.3674 +0.0114 +3.20% 19:59 09/18 EDT
OPEN
0.3450
PREV CLOSE
0.3420
HIGH
0.3700
LOW
0.3356
VOLUME
15.01M
TURNOVER
--
52 WEEK HIGH
16.80
52 WEEK LOW
0.1700
MARKET CAP
48.06M
P/E (TTM)
-0.1019
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average OCGN stock price target is 0.7000 with a high estimate of 0.7000 and a low estimate of 0.7000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.